Literature DB >> 32571428

Correction to: Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.

Cedric Bosteels1, Bastiaan Maes2, Karel Van Damme1, Elisabeth De Leeuw1, Jozefien Declercq1, Anja Delporte1, Bénédicte Demeyere1, Stéfanie Vermeersch1, Marnik Vuylsteke1, Joren Willaert1, Laura Bollé1, Yuri Vanbiervliet1, Jana Decuypere1, Frederick Libeer1, Stefaan Vandecasteele1, Isabelle Peene1, Bart N Lambrecht1.   

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Entities:  

Year:  2020        PMID： 32571428      PMCID： PMC7306655          DOI： 10.1186/s13063-020-04520-x

Source DB:  PubMed          Journal:  Trials        ISSN： 1745-6215            Impact factor:   2.279


  1 in total

1.  Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.

Authors:  Cedric Bosteels; Bastiaan Maes; Karel Van Damme; Elisabeth De Leeuw; Jozefien Declercq; Anja Delporte; Bénédicte Demeyere; Stéfanie Vermeersch; Marnik Vuylsteke; Joren Willaert; Laura Bollé; Yuri Vanbiervliet; Jana Decuypere; Frederick Libeer; Stefaan Vandecasteele; Isabelle Peene; Bart Lambrecht
Journal:  Trials       Date:  2020-06-05       Impact factor: 2.279
  1 in total
  2 in total

1.  Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.

Authors:  Karel F A Van Damme; Simon Tavernier; Nele Van Roy; Elisabeth De Leeuw; Jozefien Declercq; Cédric Bosteels; Bastiaan Maes; Marieke De Bruyne; Delfien Bogaert; Victor Bosteels; Levi Hoste; Leslie Naesens; Piet Maes; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Pieter Depuydt; Eva Van Braeckel; Filomeen Haerynck; Bart N Lambrecht
Journal:  Front Immunol       Date:  2020-11-20       Impact factor: 7.561

2.  Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

Authors:  Hillard M Lazarus; Carolyn E Ragsdale; Robert Peter Gale; Gary H Lyman
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.